Silence Therapeutics Seeks $150M in U.S. ADS Offering

Event summary

Silence Therapeutics plans a $150M public offering of American Depositary Shares (ADSs) in the U.S.
Each ADS represents three ordinary shares, with an additional 15% option for underwriters.
The offering is registered under the U.S. Securities Act and subject to market conditions.
Jefferies, Morgan Stanley, Cantor Fitzgerald & Co., and William Blair are joint book-running managers.

The big picture

Silence Therapeutics' $150M ADS offering reflects the growing demand for innovative siRNA therapies, as biotech firms seek to capitalize on advancements in gene-silencing technology. The move aligns with broader industry trends of raising capital to fund clinical-stage pipelines, particularly in areas with high unmet medical needs.

What we're watching

Capital Deployment: How Silence Therapeutics will allocate the $150M proceeds to advance its siRNA pipeline.
Market Conditions: Whether favorable market conditions will ensure the offering's success at the proposed terms.
Pipeline Progress: The pace at which Silence can translate this funding into clinical milestones for its rare and common disease targets.